Primer: Keymed Biosciences (2162 HK) - Aug 2026
Keymed is successfully transitioning into a commercial-stage biopharmaceutical company, anchored by the recent multi-indication approval of its...
94 Views
𝛼SK or SearchENTITY
Keymed Biosciences (2162 HK)
Keymed Biosciences (2162 HK)
104
Analysis
Health Care • China
Keymed Biosciences is a biotechnology company focused on the in-house discovery and development of innovative biological therapies for autoimmune diseases and oncology. Their pipeline includes over 50 programs, with key products like Kangyueda® (Stapokibart, CM310) for atopic dermatitis, chronic rhinosinusitis with nasal polyps, and seasonal allergic rhinitis. The company was founded in 2016 and is headquartered in Chengdu, China.
morex